share_log

Merit Medical Launches the Micro ACE Advanced Micro-Access System

Merit Medical Launches the Micro ACE Advanced Micro-Access System

Merit Medical 推出 Micro ACE 高級微接入系統
GlobeNewswire ·  03/19 09:25

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases

Micro ACE 結合了剛度和彈性的獨特平衡,可在具有挑戰性的案例中成功實現微接入

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation.

猶他州南喬丹,2024年3月19日(GLOBE NEWSWIRE)——醫療保健技術的全球領導者Merit Medical Systems, Inc.(納斯達克股票代碼:MMSI)今天宣佈其經美國食品藥品監督管理局(FDA)批准的Micro ACE高級微訪問系統的商業發佈。Merit 還打算向 Micro ACE 申請 CE 標誌認證。

The Micro ACE system is the latest innovation in the Merit Vascular portfolio. The comprehensive portfolio includes a full range of percutaneous access and closure devices. Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Micro ACE 系統是 Merit Vascular 產品組合中的最新創新。全面的產品組合包括全系列的經皮穿刺和封閉設備。Micro ACE 結合了剛度和彈性的平衡,旨在實現各種血管解剖結構的微接入。

Interventional procedures utilizing micro-access are commonly performed to diagnose and open narrowed (i.e., atherosclerotic) blood vessels. Atherosclerosis is an inflammatory condition that develops when there is a buildup of plaque inside the arteries. Diseases linked to atherosclerosis, such as coronary and peripheral artery disease, are the leading cause of death in the United States.1

使用微通道的介入手術通常用於診斷和打開狹窄(即動脈粥樣硬化)的血管。動脈粥樣硬化是一種炎症性疾病,當動脈內有斑塊積聚時就會發生。與動脈粥樣硬化相關的疾病,例如冠狀動脈和外周動脈疾病,是美國的主要死因。1

To facilitate such interventional procedures, the Micro ACE balances stiffness and flexibility to offer twice the resistance to kink and compression over the leading competitor. 2 It is also 9% stiffer than the leading standard micro-introducer. 2 In addition, a unique marker tip design allows for nine times greater visibility under fluoroscopy for accurate positioning needed at the start of a procedure.2 Merit is pursuing patents on Micro ACE technology in the United States and internationally.

爲了便於進行此類介入手術,Micro ACE 平衡了剛度和靈活性,其抗扭結和壓縮能力是主要競爭對手的兩倍。 2 它的硬度也比領先的標準微型導入器高9%。 2 此外,獨特的標記筆尖設計可在透視鏡下將能見度提高九倍,從而在手術開始時實現所需的精確定位。2 Merit 正在美國和國際上申請微型 ACE 技術的專利。

Learn more about the Micro ACE.

了解有關 Micro ACE 的更多信息。

"Merit has always looked for opportunities to improve patient care. Micro ACE leverages our experience with reinforced sheath design to improve a procedure that is done over and over each day," said Fred P. Lampropoulos, Merit's Chairman and CEO. "We are excited to partner with interventional physicians to advance vascular access."

“Merit 一直在尋找改善患者護理的機會。Micro ACE利用我們在加固護套設計方面的經驗來改進每天反覆進行的手術。” Merit董事長兼首席執行官弗雷德·蘭普羅普洛斯說。“我們很高興能與介入醫生合作推進血管通路。”

ABOUT MERIT MEDICAL

關於美德醫療

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,000 people worldwide.

Merit Medical Systems, Inc. 成立於1987年,從事專有的一次性醫療器械的開發、製造和分銷,用於介入、診斷和治療程序,尤其是心臟病學、放射學、腫瘤學、重症監護和內窺鏡檢查。Merit 擁有一支總計 700 多人的國內和國際銷售隊伍和臨床支持團隊,爲全球客戶醫院提供服務。Merit 在全球擁有大約 7,000 名員工。

TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

商標
除非另有說明,否則本新聞稿中使用的商標和註冊商標均爲Merit Medical Systems, Inc.、其子公司或其許可方的財產。

CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com

聯繫人
公關/媒體查詢
莎拉·康斯托克
美瑞醫療
+1-801-432-2864 | sarah.comstock@merit.com

INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com

投資者查詢
邁克·皮奇尼諾,特許金融分析師,IRC
韋斯特威克-ICR
+1-443-213-0509 | mike.piccinino@westwicke.com

1. National Heart, Lung, and Blood Institute (NIH). 2022. "Atherosclerosis." Last modified March 24, 2022. Accessed March 18, 2024.

1。國家心肺血液研究所(NIH)。2022年。“動脈粥樣硬化。”上次修改時間爲2022年3月24日。於 2024 年 3 月 18 日訪問。

2. Data on File.

2。文件中的數據。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論